Dusa Pharma (Dusa)

[surf1944]

6:31AM DUSA Pharma demonstrates positive results in Phase 2 Actinic Keratoses extremities study; study showed a statistically significant lesion reduction (DUSA) 5.38 : Co announced results of an investigational study designed to examine and compare the safety and efficacy of broad area application of the Levulan Kerastick with or without occlusive dressing in conjunction with the BLU-U for the treatment of minimally to moderately thick actinic keratoses on the upper extremities. The study showed a statistically significant lesion reduction and complete clearance of actinic keratoses of the extremities when compared to treatment with vehicle. The use of occlusion resulted in a statistically significant improvement in lesion clearance rates compared to treatment without occlusion. The safety profile seen in this study is consistent with what has been seen in previous clinical studies involving Levulan Photodynamic Therapy and is similar to that seen in the current labeling.